Shilpa Medicare Limited receives in-principle approval from DRDO for technology transfer, manufacture and supply of 2-Deoxy-D-G1ucose

Shilpa Medicare Limited (Shilpa), a research-led global integrated pharmaceutical company, today hereby announces that it has received an in-principle approval from Defence Research & Development Organisation (DRDO) to manufacture and sale of 2-Deoxy-D-Glucose (2DG).

2DG has been given emergency approval by the Drug Controller General of India (DCGI) for COVID-19 patients in the country. Shilpa Medicare Limited is only the second company in India to have entered into similar arrangement with DRDO.

Shilpa has been continuously striving to contribute towards the fight against COVID-19 and this is yet another step by Shilpa after its recently announced arrangement for manufacture and supply of Sputnik V vaccine.

Shares of SHILPA MEDICARE LTD. was last trading in BSE at Rs.548.8 as compared to the previous close of Rs. 554.65. The total number of shares traded during the day was 25283 in over 1114 trades.

The stock hit an intraday high of Rs. 561.95 and intraday low of 545. The net turnover during the day was Rs. 13989088.

Source : Equity Bulls

Keywords